All New ESRD IV Drugs Should Get Break From Medicare Payment Bundle – Amgen
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS should not limit proposed transitional payments for IV and injectable ESRD drugs based on the current criteria for bundling, Amgen says. Company's approach could benefit its new IV caclimimetic drug candidate.
New to Pink Sheet?
Request a free trial today!
Register for our free email digests:
Register for our free email digests:
